Business
Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases
GAITHERSBURG, Md., April 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™
About this update from Novavax, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., April 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC, April 3 to 6, 2023, and the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023.\nAt WVC, Novavax will present data on its COVID-19 prototype vaccine as a booster and its CIC. Novavax will also host an Insights and Tools to Counter Vaccine Hesitancy roundtable on April 4, and participate in a panel discussion on The Future of Safety for New Vaccines on April 5. In addition, Novavax has been named a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards (ViE) in the Best New Vaccine Technology/Platform Award and Best COVID Vaccine Award categories. Winners will be announced in-person at the ViE Awards ceremony during WVC on April 4.\nAt ECCMID, the Company will present the CIC data and four poster presentations on its COVID-19 prototype vaccine.\nNovavax presentations during WVC: \nAuthor \nPresentation title\nDetails\nDunkle, L\nNovavax COVID-19 Vaccine: Latest Booster Data and Clinical Updates\nOral Presentation\nApril 5, 2023\n10:10am (EDT)\nShinde, V\nUpdate on Novavax Influenza and COVID-Influenza Combination Vaccine\nOral Presentation \nApril 5, 2023\n3:25pm (EDT)\nFix, J\nSafety surveillance for COVID-19 vaccines: challenges in the pandemic and endemic settings\nOral Presentation\nApril 5, 2023\n12:10pm (EDT)\nNovavax presentations during ECCMID: \nAuthor \nPresentation title \nDetails \nShinde, V \nImmunogenicity of a novel COVID-Influenza Combination (CIC) vaccine assessed with response surface modelling (RSM) \nOral Presentation \nAbstract #02042 \nApril 16, 2023 \n8:30am (CEST) \nToback, S \nInterim analysis of an observer-blinded, randomized phase 3 study to evaluate the safety and immunogenicity of a single booster of the NVX-CoV2373 vaccine in adults previously vaccinated with the BBIBP-CorV vaccine \nPoster Presentation \nPoster #P2698 \nApril 17, 2023 \n12:00pm (CEST) \nMarchese, A \nReported pregnancy outcomes across NVX-CoV2373 COVID-19 vaccine primary series and booster dose clinic...